

itself stimulates the Langerhans cells or that some substances from skin bacterial flora play the role of danger signals. It is possible that a wet gauze patch stuck on the stratum corneum for a prolonged period stimulates the Langerhans cells. In fact, there are reports that some physical stimuli to the stratum corneum, such as tape-stripping or low frequency ultrasound, activate the Langerhans cells [18,37].

Our experiments clearly indicated that the ear skin was immunized more efficiently than the abdominal skin by the prolonged TCI procedure. It is known that the differences in skin structure, such as thickness of the stratum corneum and the density of Langerhans cells, among anatomic skin sites influence the penetration efficiency of low molecular percutaneous drugs [31,32]. The difference between the structures of the ear skin and abdominal skin may explain our observation. Thus, our observation indicates that skin anatomy is an important factor influencing the efficiency of TCI.

CT or LT has strong mucosal adjuvanticity. CT-adjuvanted or LT-adjuvanted TCI induces the mucosal antibody response, in addition to the systemic immune response [6,7,15,28,33,34]. Interestingly, we observed that non-adjuvanted prolonged TCI with OVA induced substantial antigen-specific IgG and IgA antibodies in the feces of mice although the magnitude of antibody production was significantly less as compared to that induced by CT-adjuvanted TCI. Our observation indicated that the mucosal immune response to TCI could be also induced even in the absence of CT or LT.

We observed substantial antibody responses in all the 3 strains of mice immunized by the prolonged non-adjuvanted TCI. This observation suggests that this modified TCI would be feasible for a wide range of genetic backgrounds. However, there were some significant differences among the 3 strains with regard to the magnitude of serum antibody productions. The C57BL/6 mice were the most sensitive to the prolonged TCI, while the C3H/He mice were the least sensitive. The response of the BALB/c mice was intermediate. Another group has previously reported a similar hierarchy in the sensitivity to TCI [38]. They used CT as an adjuvant and hypothesized that the hierarchy reflected the difference in the sensitivity to CT based on former experiments which indicated that the plasma IgG response to CT following oral or parenteral administration was under the genetic control of the I-A region of the H-2 major histocompatibility complex [39–41]. Here, we observed the same hierarchy regardless of the use of CT, suggesting that other mechanism(s) govern the sensitivity to TCI.

We applied the prolonged TCI method by using the Ttd as a model vaccine antigen and successfully induced significant serum antibody responses. Indeed, CT had an adjuvant effect in the prolonged TCI using Ttd, but non-adjuvanted prolonged TCI using the Ttd also induced substantial Ttd-specific antibodies in the sera of mice after the second booster immunization. The mice immunized with the Ttd according to the prolonged TCI method, adjuvanted and non-adjuvanted, survived with no clinical symptoms after

challenge with a lethal dose of the tetanus toxin. These results suggest that non-adjuvanted prolonged TCI method is a feasible vaccination method for infectious diseases.

Thus far, the TCI method has been shown to be functional in various disease models, including bacterial and viral infections, malignancies [26,35], and Alzheimer's disease [36], using various animals, e.g., mice, rats [20], sheep [22], cattle [24], chickens [21], and humans [12,19]. To develop an effective TCI strategy for different aims, the TCI protocol with regard to antigens, adjuvants, skin treatments, etc. requires optimization. In this study, we pointed out the importance of the duration of antigen presence on the skin during the TCI procedure and showed that substantial antibodies were induced by non-adjuvanted TCI of 16-h duration. Our observations improve the understanding regarding the TCI mechanisms and offer a practical option for developing a safe and effective method for transcutaneous vaccination.

References

- [1] Bos JD. The skin as an organ of immunity. *Clin Exp Immunol* 1997;107(Suppl. 1):3–5.
- [2] Chuong CM, Nickoloff BJ, Elias PM, Goldsmith LA, Macher E, Maderon PA, et al. What is the 'true' function of skin? *Exp Dermatol* 2002;11:159–87.
- [3] Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. *Nature* 1998;391:851.
- [4] Beignon AS, Briand JP, Muller S, Partidos CD. Immunization onto bare skin with heat-labile enterotoxin of *Escherichia coli* enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. *Immunol* 2001;102:344–51.
- [5] Godefroy S, Goestch L, Plotnicky-Gilquin H, Nguyen TN, Schmitt D, Staquet MJ, et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV). *Vaccine* 2003;21:1665–71.
- [6] Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against *Chlamydia muridarum* genital tract infection. *Infect Immun* 2004;72(2):1019–28.
- [7] Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. *Vaccine* 2006;24:6110–9.
- [8] Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. *Crit Rev Ther Drug Carrier Syst* 2001;18(5):503–26.
- [9] Partidos CD, Beignon AS, Briand JP, Muller S. Modulation of immune responses with transcutaneously deliverable adjuvants. *Vaccine* 2004;22:2385–90.
- [10] Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. *Infect Immun* 1999;67(3):1100–6.
- [11] Warger T, Schild H, Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. *Immunol Lett* 2007;109:13–20.
- [12] Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. *Nature Med* 2000;6(12):1403–6.
- [13] Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. *J Immunol* 2005;174(5):2476–80.

- [14] Tierney R, Beignon AS, Rappuoli R, Muller S, Searidic D, Partidos CD. Transcutaneous immunization with tetanus toxoid and mutants of *Escherichia coli* heat-labile enterotoxin as adjuvants elicits strong protective antibody. *J Infect Dis* 2003;188(5):753–8.
- [15] John M, Bridges EA, Miller AO, Calderwood SB, Ryan ET. Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. *Vaccine* 2002;20(21–22):2720–6.
- [16] Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. *Infect Immun* 2000;68(9):5306–13.
- [17] Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. *Vaccine* 2006;24(9):1282–90.
- [18] Tezel A, Paliwal S, Shen Z, Mitragori S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. *Vaccine* 2005;23:3800–7.
- [19] McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic *Escherichia coli* (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. *Vaccine* 2007;25(18):3684–91.
- [20] Mishra V, Mahor S, Rawat A, Dubey P, Gupta PN, Singh P, et al. Development of novel fusogenic vesosomes for transcutaneous immunization. *Vaccine* 2006;24(27–28):5559–70.
- [21] Heckert RA, Elankumaran S, Oshop GL, Vakharia VN. A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. *Vet Immunol Immunopathol* 2002;89(1–2):67–81.
- [22] Chen D, Colditz IG, Glenn GM, Tsomis CG. Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. *Vet Immunol Immunopathol* 2002;86(3–4):177–82.
- [23] Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, et al. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic *Escherichia coli*. *Infect Immun* 2002;70(3):1056–68.
- [24] Morrow CK, Colditz IG, Cope RB. Stimulated solar UVB exposure inhibits transcutaneous immunization to cholera toxin via an irradiated skin site in cattle. *Vet Immunol Immunopathol* 2001;83(1–2):107–14.
- [25] Godefroy S, Peyre M, Garcia N, Muller S, Searidic D, Partidos CD. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin. *Infect Immun* 2005;73(8):4803–9.
- [26] Frankenburg S, Grinberg I, Bazak Z, Fingerut L, Pitcovski J, Gorodetsky R, et al. Immunological activation following transcutaneous delivery of HR-gp100 protein. *Vaccine* 2007;25(23):4564–70.
- [27] Paul A, Ceve G, Bachhawat BK. Transdermal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. *Vaccine* 1998;16(2–3):188–95.
- [28] Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, et al. Transcutaneous immunization with *Clostridium difficile* toxin A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. *Infect Immun* 2007;75(6):2826–32.
- [29] Matyas GR, Friedlander AM, Glenn GM, Little S, Yu J, Alving CR. Needle-free skin patch vaccination method for anthrax. *Infect Immun* 2004;72(2):1181–3.
- [30] Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. *Immunology* 2002;107(1):69–76.
- [31] Ya-Xian Z, Suetake T, Tagami H. Number of cell layers of the stratum corneum in normal skin—relationship to the anatomical location on the body, age, sex and physical parameters. *Arch Dermatol Res* 1999;291:555–9.
- [32] Bronaugh RL, Maibach HI. Topical absorption of dermatological products. New York: Marcel Dekker, Inc.; 2002.
- [33] Hickey DK, Bao S, Ikeda LT, Carey AJ, Beagley KW. Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. *Curr Mol Med* 2005;5(6):599–605.
- [34] Partidos CD, Moreau E, Chaloin O, Tunis M, Briand JP, Desgranges C, et al. A synthetic HIV-1 Tat protein breaches the skin barriers and elicits Tat-neutralizing antibodies and cellular immunity. *Eur J Immunol* 2004;34(12):3723–31.
- [35] Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. *Proc Natl Acad Sci USA* 2000;97(1):371–6.
- [36] Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. *Proc Natl Acad Sci USA* 2007;104(7):2507–12.
- [37] Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. *J Invest Dermatol* 1997;109(2):175–82.
- [38] Scharton-Kersten T, Glenn GM, Vassell R, Yu J, Walwender D, Alving CR. Principles of transcutaneous immunization using cholera toxin as an adjuvant. *Vaccine* 1999;17:537–43.
- [39] Elson CO, Ealding W. Genetic control of the murine immune response to cholera toxin. *J Immunol* 1985;135:930–2.
- [40] Elson CO, Ealding W. Ir gene control of the murine secretory IgA response to cholera toxin. *Eur J Immunol* 1987;17:425–8.
- [41] Elson CO. Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and Igs genes. *Infect Immun* 1992;60:2874–9.

Two vaccine toxicity-related genes Agp and Hpx could prove useful for pertussis vaccine safety control

Isao Hamaguchi^{a,1}, Jun-ichi Imai^{b,1}, Haruka Momose^{a,1}, Mika Kawamura^{b,d}, Takuo Mizukami^a, Hiroshi Kato^a, Seishiro Naito^a, Jun-ichi Maeyama^a, Atsuko Masumi^a, Madoka Kuramitsu^a, Kazuya Takizawa^a, Masayo Mochizuki^a, Masaki Ochiai^c, Akihiko Yamamoto^c, Yoshinobu Horiuchi^c, Nobuo Nomura^e, Shinya Watanabe^b, Kazunari Yamaguchi^{a,*}

^a Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

^b Department of Clinical Informatics, Tokyo Medical and Dental University, Tokyo, Japan

^c Department of Bacterial Pathogenesis and Infectious Control, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

^d Medicrome, Inc., Sendagaya, Shibuya-ku, Tokyo 151-0051, Japan

^e Biological Information Research Center, National Institute of Advanced Industrial Science and Technology, Japan

Received 31 July 2006; received in revised form 21 December 2006; accepted 28 December 2006

Available online 16 January 2007

Abstract

Conventional animal tests such as leukocytosis promoting tests have been used for decades to evaluate toxicity of pertussis vaccine. Here, we examined gene expression in relation to the vaccine toxicity using a DNA microarray. Comparison of conventional animal test data with the DNA microarray-based gene expression data revealed a gene expression pattern highly correlated with leukocytosis in animals. Of 10,490 rat genes analyzed, two genes, α 1-acid-glycoprotein (Agp) and hemopexin (Hpx), were found up-regulated by the toxin administration in a dose-dependent manner (assayed by a quantitative PCR based on the microarray). Variation of the gene expression was very small amongst the test animals, and the results were highly reproducible. These findings suggest that gene expression analysis of vaccine-treated animals can be used as an accurate and simple method of pertussis vaccine safety assessment.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: Pertussis vaccine; Microarray; Quantitative RT-PCR; Agp; Hpx; Safety test; Pertussis toxin

1. Introduction

Although regarded as one of the great public health successes, vaccines are not absolutely safe. While most adverse events associated with vaccines are minor and self-limiting, some vaccines have been associated with rare but serious health consequences.

Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium *Bordetella pertussis*, which was first isolated in 1906 [1]. Outbreaks of pertussis were first described in the 16th century [2], and in the 20th century, pertussis was one of the most common childhood diseases and a major cause of childhood mortality. Prior to the availability of whole-cell pertussis vaccine in the 1940s, annual morbidity of pertussis exceeded 200,000 cases. Pertussis vaccine has long been used in many countries as the effective protective measure against the disease, leading to a dramatically decreased incidence of the disease.

* Corresponding author. Tel.: +81 42 561 0771.

E-mail address: kyama@nih.go.jp (K. Yamaguchi).

¹ These authors contributed equally to this work.

Both whole cell and acellular pertussis vaccines are now available against pertussis infection. The whole cell pertussis vaccine is composed of a suspension of formalin-inactivated *B. pertussis* cells. In contrast, the acellular pertussis vaccine contains purified, inactivated components of *B. pertussis* cells. Acellular pertussis vaccines now in use contain primarily pertussis toxin (PT) and filamentous hemagglutinin [3]. Pertussis vaccines cause local reactions, such as pain, redness, or swelling, in 20–40% of treated children, and systemic events, such as fever of 105 °F or higher, febrile seizures, and hypotonic–hyporesponsive episodes, have been reported [4]. The Japanese Ministry of Health Labour and Welfare reported that the adverse reactions, such as fever, pain, edema, and purpura, were observed in 237 people in 5.4 million vaccine-treated people in 2003.

While the mechanisms underlying adverse reactions remain unknown, vaccines should undergo extensive safety and efficacy tests to control vaccine quality. Fundamental is the assurance that any vaccine destined for public use is manufactured under Good Manufacturing Practices (GMP) and has passed appropriate pre-release lot testing for purity and potency, for which manufacturers must submit samples of each vaccine lot and their own test results. In Japan as in other countries, all the vaccines must conform to the “Minimal Requirement of Biological Products” and are obliged to pass national control tests [5].

Pertussis vaccine toxicity causing adverse reactions, is evaluated by the conventional animal toxicity tests, which are based on the peripheral white blood cell (WBC) counts in mice after subcutaneous or intra-peritoneal injection [6,7]. In mice, PT blocks extravasation reactions that mediate lymphocyte homing from peripheral blood to solid lymphoid tissues [8,9]. For a vaccine to be considered safe, an increase in the WBC count in mice should not exceed 0.5 LPU (leukocytosis promoting unit)/ml at day 3 after injection [5]. Pertussis vaccine toxicity is also typically assessed by the histamine sensitization test. In this test, mouse rectal temperatures are monitored after histamine challenge on the fourth day of vaccine injection [10]. To develop more sensitive and more reproducible methods, we undertook comprehensive gene expression analysis of rats after administration of the pertussis vaccine by using DNA microarrays [11]. Hybridization of labeled nucleic acid from a sample to the microarrays identifies genes expressed in the specific sample. This approach allows simultaneous analysis of expression of the multiple genomes in a single cycle experiment. This approach has already been used for evaluation of side effects of drugs [12].

2. Materials and methods

2.1. Animals

Male Wistar rats (8 weeks) were obtained from SLC (Tokyo, Japan). All animals were housed in rooms maintained at 23 ± 1 °C, with 50 ± 10% relative humidity, and

12-h light:12-h dark cycles at least 1 week prior to the test challenge. Rats typically weighed 160–200 g on arrival.

2.2. Vaccines and toxin

Reference pertussis vaccine (reference vaccine; RE) was a lyophilized whole cell preparation of pertussis organisms incompletely inactivated by formaldehyde, used for National Quality Control Tests on pertussis vaccine in Japan since 1981. It was reconstituted in 12 ml of physiological saline, and 5 ml were injected intra-peritoneally (IP). PT (pertussis toxin) are prepared and purified by ammonium-sulfate fractionation and sucrose density gradient centrifugation, and treated with formaldehyde to destroy the toxic activity, and added with aluminum salt. PT (Wako Chemicals, Osaka, Japan) and PV (a generous gift of The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) were adjusted to 5 µg/ml (PT concentration). RE, PV, and different concentrations of PT were injected into rats IP (5 ml/rat). Five milliliters of saline (SA) were injected as a control.

2.3. WBC counts

A leukocytosis-promoting test was performed according to the Minimum Requirements of Biological Products [5]. Ten microliters of each blood samples were used for WBC counting. The count was performed with a Z1 coulter particle counter (Beckman Coulter, Fullerton, CA). Three rats per group were treated by RE, PT, PV, and SA, and were analyzed on day 1–4 post-treatment. The experiments were performed three times.

2.4. Histology

Vaccine-treated livers were harvested from rats and fixed in Bouin's Solution (Sigma, St. Louis, MO) and 4% (w/v) paraformaldehyde at 4 °C for 48 h. After fixation, tissues were dehydrated through a series of graded alcohols and xylene and embedded in paraffin. Chilled paraffin blocks were cut into 4–6 µm sections, which were floated onto glass slides and dried overnight and stained with Hematoxylin and eosin (HE) and periodic acid Schiff (PAS). Cellular polysaccharide deposits were detected using the PAS reaction. Three rats per group were treated by RE, PT, PV, and SA, and were analyzed on day 1–4 post-treatment. The experiments were performed twice. Immunohistochemical staining was carried out as described [13]. Briefly, after blocking with 3% BSA in PBS, 4 µm sections were incubated overnight with anti- α 1-acid-glycoprotein (A_gp) (AgriSera, Vännäs, Sweden) at 4 °C overnight. Signals were detected with a VECTASTAIN ABC Kit (Vector Laboratories, Inc., Burlingame, CA). Nuclei were stained with hematoxylin.

In situ hybridization was performed essentially as described [14]. *In situ* hybridization using liver sections was carried using digoxigenin (DIG)-labeled RNA probes specific for A_gp (Genebank accession number

NM053288, 0.77 kb) and *Hpx* (NM053318, 1.48 kb). All cRNA probes were generated from the corresponding coding sequences. *Agp* forward primer: 5-tgcacatggttcttgcgtt-3, reverse primer; 5-gaatcgaggtgcacaggagt-3, *Hpx* forward primer; 5-cgctactactgcttcagg-3, reverse primer; 5-atgctgtcacttctctggg-3. *In situ* hybridization with the antisense or sense probes was incubated at 42 °C for 24 h in a humidified chamber. Hybridized DIG-labeled cRNA was detected using AP labeled-anti-DIG mouse fab fragments (Roche Diagnostics, Lewes, UK). The sections were treated with BCIP/NBT and mounted in Gel mount (Biomed, Foster City, CA). Three rats per group were treated by RE, PT (5 µg/ml), PV, and SA, and were analyzed on day 1–4 post-treatment. The experiments were performed twice.

2.5. RNA preparation

Rats were sacrificed to obtain the lateral left lobe of the liver. Organs were immediately frozen in liquid nitrogen for storage. Thawed tissue was homogenized and mixed with an ISOGEN reagent (NIPPON GENE, Tokyo, Japan). Total RNA was prepared from the lysate in accordance with the manufacturer's instructions. Poly(A)+RNA was prepared from total RNA with a Poly(A) Purist Kit (Ambion, Austin, TX), according to the manufacturer's instructions.

2.6. Microarray preparation and expression profile acquisition

For the microarray analysis, three rats per group were treated by RE, PT (5 µg/ml), PV, and SA, and livers from each group were analyzed on day 1–4 post-treatment. Totally 48 liver samples were analyzed for this experiment.

A set of synthetic polynucleotides (80-mers) representing 11,464 rat transcripts derived from 10,490 independent genes and including most of the RefSeq clones deposited in the NCBI database (MicroDiagnostic, Tokyo, Japan) was arrayed on aminosilane-coated glass slides (Type I; Matsunami, Kishiwada, Japan) with a custom-made arrayer [15,16]. Poly(A)+RNA (2 µg) was labeled with SuperScript II (Invitrogen, Carlsbad, CA) and Cyanine 5-dUTP for each sample or Cyanine 3-dUTP (Perkin-Elmer, Boston, MA) for a rat common reference RNA (MicroDiagnostic). Labeling, hybridization, and washes of microarrays were performed with a Labeling & Hybridization Kit (MicroDiagnostic) according to the manufacturer. The rat common reference RNA was purchased as a single batch and labeled as an aliquot with Cyanine-3 for a single microarray side by side with each sample labeled with Cyanine-5. Hybridization signals were measured using a GenePix 4000A scanner (Axon Instruments, Whipple Road Union City, CA) and then processed into primary expression ratios ([Cyanine 5-intensity obtained from each sample]/[Cyanine 3-intensity obtained from common reference RNA]), which are indicated as 'median of ratios' in GenePix Pro 3.0 software (Axon Instruments). Normalization was performed for the median of ratios (pri-

mary expression ratios) by multiplying normalization factors calculated for each feature on a microarray by the GenePix Pro 3.0 software.

2.7. Data analysis

Data processing and hierarchical cluster analysis were performed using Excel (Microsoft, Redmond, WA) and a MDI gene expression analysis software package (MicroDiagnostic). The primary expression ratios were converted into log₂ values (log₂ Cyanine-5 intensity/Cyanine-3 intensity) (designated log ratios) and compiled into a matrix (designated primary data matrix). To predict the most obvious differences obtained from cluster analysis of the primary data matrix, we extracted genes with log₂ ratios over 1 or under -1 in at least one sample from the primary data matrix and subjected them to two-dimensional hierarchical cluster analysis for samples and genes. To identify genes demonstrating significant changes in expression, we undertook the following: (i) mean averages of log₂ ratios were calculated for each gene from data sets of day 1 SA- and RE-treated samples; (ii) standard deviations were calculated for each gene; (iii) the difference in mean averages between day 1 SA- and RE-treated samples was calculated for each gene and divided by the sum of the corresponding standard deviation values. A value of the difference of the mean averages/the sum of the standard deviations was defined as an expression signal/noise index for each gene. We chose the top 150 genes exhibiting the highest expression signal/noise indexes and extracted expression data corresponding to the 150 genes from the primary data matrix for all the samples, which was subsequently subjected to two-dimensional hierarchical cluster analysis for samples and genes.

2.8. Quantitative RT-PCR analysis

Total RNA was used to synthesize first strand cDNA using a First-strand cDNA Synthesis Kit (Life Science, Inc., St. Petersburg, FL), according to the manufacturer's instructions. Expression levels of *Agp* and *Hpx* were analyzed by quantitative (Q) reverse transcriptase-polymerase chain reaction using a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) with 7500 Fast System SDS Software Version 1.3. cDNA was amplified for Q-PCR using SYBR Green I (Molecular Probes, Inc.) to detect PCR product. One microliters of six-fold diluted cDNA was used in a 20-µl final volume reaction containing 10 µl SYBR Green[®] PCR Master Mix (Applied Biosystems), 0.2 µM *Agp* fwd primer (5'-GCTGGAGCTGGAGAAGGAGACT-3'), and 0.2 µM *Agp* rev primer (5'-ACAGTCCCCGGAGTTCAGAGA-3'). The 7500 Fast System was programmed to run an initial polymerase activation step at 95 °C for 10 min followed by 40 cycles of denaturation (95 °C for 15 s) and extension (60 °C for 1 min), and product synthesis was monitored at the end of the extension step of each cycle. The same conditions were used with primers 0.05 µM *Hpx*

fwd (5'-CTGCCTCAGCCCCAGAAAGT-3') and 0.05 μ M Hpx rev (5'-GGGTGGGCTGGGCTAATTC-3'). Agp and Hpx values were normalized against rat β -actin (0.1 μ M fwd 5'-ACCGTGAAAAGATGACCCAGATC-3'; rev 5'-GACCAGAGGCATACAGGGACAAC-3').

2.9. Western blot analysis

One day after treatment, livers were rapidly removed from diethylether anesthetized rats, washed in PBS, and weighed. After dicing, tissue was homogenized in PBS containing protease inhibitors and lysed in PBS containing protease inhibitors, 1% (w/v) Nonidet P-40, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, and 10 mM Na-EDTA. Supernatants were collected after centrifugation at $10,000 \times g$ for 20 min and used as a whole liver lysate. Fifty micrograms of the lysate was subjected to SDS-PAGE (10% acrylamide) and the separated proteins were transferred to an Immobilon-P membrane (Millipore, Watford, UK). After incubation in TBS (20 mM Tris-HCl (pH 8.0) and 100 mM NaCl) containing 5% (w/v) BSA, the membrane was incubated with anti-AGP (AgriSera) or anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies for 1 h and further incubated with HRP-conjugated anti-goat or anti-rabbit IgG. Peroxidase activity was visualized with a LAS 3000 bioimaging analyzer (Fuji Film, Tokyo, Japan).

2.10. Statistical analysis

To evaluate the statistical significance of the difference in expression level of Agp and Hpx, the Student's *t*-test was used to calculate the *P*-value.

3. Results

3.1. Vaccine-treated rats demonstrated leukocytosis in peripheral blood

Animals were treated with 5 ml of reference pertussis vaccine (RE), purified pertussis vaccine (PV), pertussis toxin (PT), or saline (SA), and the peripheral WBCs were counted at days 1, 2, 3, and 4. RE is an incompletely inactivated whole cell vaccine for the reference of PT toxicity. PT is a purified pertussis toxin. To evaluate dose-response to PT, mixture of a constant amount of PV and varying amount of PT, 0.2, 1.0, and 5.0 μ g/ml were used for injection (coded as PV + PT0.2, PV + PT1, and PV + PT5, respectively). Three rats per group were analyzed in each day after sample injection. RE-treated rats started to show leukocytosis at day 2; the leukocyte count continued to increase reaching values three times higher than the baseline at day 4 (Fig. 1). PV + PT5-treated rats also demonstrated leukocytosis, as did RE-treated rats. By contrast, PV- and SA-treated animals showed normal WBC counts. WBC counts of both PV + PT0.2- and PV + PT1-treated rats were within the normal range.




Fig. 1. Leukocytosis-promoting activity in RE- and PT-treated animals. The effects of RE-, PT-, PV-, SA-treatment were analyzed by leukocytosis-promoting tests. Various PT concentrations (0.2–5.0 μ g/ml) were added to PV and a WBC count was performed at days 0, 1, 2, 3, and 4. Changes in WBC count are indicated by the mean increase \pm S.D. of three independent experiments. Each value was compared to the corresponding control SA.

3.2. Histological analysis in vaccine-treated rats

To analyze the effect of pertussis vaccine on rat liver, we performed histological study on day 1–4 post-treatment twice. As shown in Fig. 2, SA-, PV + PT-, and RE-treated livers showed no significant change in HE stained sections. Since periodic acid Schiff (PAS)-positive glycogen granules in hepatocytes are sensitive to strong stresses by drugs, toxic agents, starvation, and hypoxic conditions, PAS staining was also evaluated. At day 1, we have remarkable change in RE samples by PAS staining, however we could not detect the same change in other samples (Fig. 2). The same results that only RE affect the PAS staining in the hepatocyte were confirmed in the other time point (day 2–4, data not shown). These findings indicated that histological analysis could be useful to monitor toxicity effects induced by RE vaccine, but did not reflect toxicity induced by PT when added to PV.

3.3. Microarray assay of vaccine-treated liver

To evaluate the effect of pertussis vaccine on the gene expression in the liver, we prepared three rats per group. RE-, PT- (5 μ g/ml), PV-, and SA-treated groups were sacrificed to take liver samples each at days 1, 2, 3, and 4. Total 48 independent liver tissue samples were analyzed. We labeled poly(A)⁺ RNA purified from the samples and from a rat common reference RNA with Cyanine-5 and Cyanine-3, respectively. Next, we hybridized them to microarrays representing 11,464 transcripts derived from 10,490 independent genes including most of the RefSeq clones deposited in the NCBI database. Hybridization signals were processed into expression ratios as \log_2 values (designated \log_2 ratios) and compiled into a matrix designated as the primary data matrix (see Section 2). To extract genes whose expression levels altered specifically to RE-administration at day 1 from the primary data matrix, we conducted the statistical operations described in Section 2. When the cluster analysis for liver samples was performed, two large clusters were obtained, and




Fig. 2. Histochemical study of RE- and PT-treated liver. The left lobes of sample treated liver were sectioned and stained with HE and PAS. (A) RE-, PV-, PV + PT1- (PT 1.0 $\mu\text{g}/\text{ml}$), PV + PT5- (PT 5.0 $\mu\text{g}/\text{ml}$), and SA-treated liver were stained with HE. (B) Sectioned samples were stained with PAS plus HE and analyzed at low (upper panel) and high (lower panel) magnification.

RE-treated samples (1 day after RE administration, RE/1d) showed cluster different from others (Fig. 3A). We identified top 150 genes exhibiting the highest scores whose expression was either increased or decreased by RE-administration at day 1 (RE-1d in Fig. 3B). Of those genes, 61 are related to metabolism, 21 encode signal transduction molecules, and the rest are classified as toxic response-, inflammation-, and human-disease-related genes (Fig. 3C). Functions of about one-third of these 150 genes are unknown.

3.4. Identification of toxicity-specific genes

To identify toxicity-related genes from the microarray data, we compared results from RE-treated samples with SA-treated ones. *Agp*, *S100a8*, *Phyh*, *Got1*, *Lbp*, and *Hpx* genes showed the greatest increase in expression level in RE-treated samples (Table 1). When PT-treated animal samples were compared with PV-treated ones, expressions of *Hpx*, *Acmsd*, *Tat*, and *Cyp8b1* were significantly increased (Table 1). *Phyh*, *Got1*, *Acmsd*, *Tat*, and *Cyp8b1* participated in metabolism. On the other hand, *Agp*, *S100a8*, *Lbp*, and *Hpx* participated in inflammation. To quantify expression of candidate genes, the liver cDNAs were analyzed by quantitative RT-PCR (Fig. 4, lower panel), and compared with the microarray data (Fig. 4, upper panel). Liver cDNA were prepared from two or three rats, and two independent quantification experiments were performed. *Agp* and *Hpx* genes demonstrated high expression in RE- and PT-treated liver, and their expression was low in PV- and SA-treated liver (Fig. 4). Both were then chosen for further quantitative analysis.

3.5. *Agp* and *Hpx* expression in the liver

For confirmation, we performed *in situ* hybridization and immunohistochemistry. Specific probes against *Agp* clearly detected *Agp* mRNA in RE-treated liver at day 1 (Fig. 5G and H). Western blot analysis of the cell lysates showed markedly increase of AGP expression in RE-treated liver in comparison with SA-treated liver (Fig. 5Q). Strong AGP protein expression was also detected in RE-treated livers in comparison to SA-treated livers (Fig. 5R–U). From these data, we conclude that AGP is induced in liver by RE-treatment. Since there is no appropriate antibody against rat *Hpx*, we analyzed *Hpx* expression by *in situ* hybridization. *Hpx* expression was rapidly induced in hepatocytes following RE-treatment, and its expression pattern was similar to *Agp* (Fig. 5I–P). Thus, of the nine genes identified by microarray analysis, histological analysis with specific RNA probes and antibodies demonstrated the highest correlation with *Agp* and *Hpx*. Thus, we identify *Agp* and *Hpx* as toxicity-related genes and suggest that these genes could be used as biomarkers.

3.6. Detection of PT activity using Q-PCR analysis

To detect alterations in *Agp* and *Hpx* gene expressions after vaccine-treatment, we injected various concentrations of PT (0.008–5.0 $\mu\text{g}/\text{ml}$) and RE into rats. Three rats per group were analyzed. As shown in Fig. 6, expression of *Agp* and *Hpx* was tremendously high in RE-treated livers, and both genes showed a strict dependence on the concentration of PT. These genes were clearly up-regulated by PT at




Fig. 3. Gene expression profiles obtained from RE-, PT-, PV-, and SA-treated rats. (A) Genes expressed in sample-treated liver are assembled in the order obtained from the results of cluster analysis. The color bar at left shows the expression ratio vs. the common reference RNA in \log_2 ; red and blue indicate increases and decreases in the expression ratio, respectively. (B) One hundred and fifty genes represented showed significant alterations in RE-treated liver at day 1 (RE-1d). The expression pattern of the 150 genes in other samples (pink bar) showed a clear difference from RE-1d (green bar). The y-axis of the dendrogram depicts the Euclid square distance as the dissimilarity coefficient. Red and blue indicate increases and decreases in the expression ratio, respectively. (C) Genes are classified in the circle graph.

Table 1
Transcripts upregulated in RE- and PT-treated samples

Accession no.	Symbol	Definition	Molecular function	Expression ratios			
				SA	PV	PT	RE
AB018596	Cyp8b1	Rattus norvegicus mRNA for sterol 12-alpha hydroxylase, complete code	Metabolism	1.76 ± 0.15	1.86 ± 0.48	2.70 ± 0.40	3.61 ± 0.96
J00696	Agp/Orm1	Rat alpha1-acid glycoprotein (AGP) mRNA, complete cds	Inflammation	1.34 ± 0.67	1.58 ± 0.36	4.11 ± 0.38	6.30 ± 0.17
M62642	Hpx	Rat (clone pRHx1) hemopexin mRNA, complete cds	Inflammation	2.74 ± 0.37	2.82 ± 0.15	4.08 ± 0.23	5.30 ± 0.07
NM_012571	Got1	Rattus norvegicus glutamate oxaloacetate transaminase 1 (Got1), mRNA	Metabolism	0.11 ± 0.34	0.18 ± 0.24	1.12 ± 0.35	2.86 ± 0.53
NM_012668	Tat	Rattus norvegicus tyrosine aminotransferase (Tat), mRNA	Metabolism	2.55 ± 0.16	2.34 ± 0.58	3.06 ± 0.41	4.18 ± 0.55
NM_017208	Lbp	Rattus norvegicus lipopolysaccharide binding protein (Lbp), mRNA	Inflammation	1.49 ± 0.24	1.47 ± 0.18	3.59 ± 0.41	4.84 ± 0.17
NM_053674	Phyh	Rattus norvegicus phytanoyl-CoA hydroxylase (Phyh), mRNA	Metabolism	2.03 ± 0.19	2.08 ± 0.12	3.22 ± 0.37	3.78 ± 0.16
NM_053822	S100a8	Rattus norvegicus S100 calcium binding protein A8 (calgranulin A) (S100a8), mRNA	Inflammation	-5.94 ± 0.03	-5.89 ± 0.23	-5.25 ± 0.30	-3.07 ± 0.29
NM_134372	Acmsd	Rattus norvegicus 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (acmsd), mRNA	Metabolism	2.50 ± 0.42	2.10 ± 0.21	3.32 ± 0.84	4.04 ± 0.40

Cyanine 5-labeled liver RNA and Cyanine 3-labeled rat common reference RNA were competitively hybridized to microarrays. Hybridization signals were processed into primary expression ratios ([Cyanine 5-intensity obtained from each sample]/[Cyanine 3-intensity obtained from common reference RNA]), and normalized (primary expression ratios). The primary expression ratios were converted into \log_2 values (\log_2 Cyanine-5 intensity/Cyanine-3 intensity) as described in Section 2. \log_2 values for each sample were taken an average and calculated S.D.




Fig. 4. Comparison of microarray data and quantitative PCR analysis. Expression of Agp (A) and Hpx (B) from DNA microarray analysis (upper panel) is compared with real-time quantitative PCR data (lower panel). (Upper panels) Relative \log_2 ratios were extracted from the secondary data matrix for Agp and Hpx. Each symbol represents data from individual animals. Two independent experiments in microarray analysis are shown. (Lower panels) Quantitative PCR analysis of treated livers from individual animals is shown. Duplicate data from each animal is shown as black and white bars. Agp and Hpx expression was assessed relative to rat β -actin.

concentrations of 5 $\mu\text{g/ml}$ ($P < 0.05$) in comparison with SA, PV, and PT (0.008–0.2 $\mu\text{g/ml}$). At concentration of 1 $\mu\text{g/ml}$, some animals showed slight high expression of these genes in comparison with the animals treated with SA, PV or PT (0.008–0.2 $\mu\text{g/ml}$). These findings suggest that Agp and Hpx may be good candidates to monitor the PT-induced toxicity.

4. Discussion

In this study, we identified genes whose expression is affected by PT-related toxicity using DNA microarray analysis. Although the principle of nucleic acid hybridization is not new, microarrays have opened the way for parallel




Fig. 5. Expression of Agp and Hpx in RE-, PT-, PV-, and SA-treated liver. Expression of Agp mRNA analyzed by *in situ* hybridization. SA-, PV-, PT-, and RE-treated liver was analyzed at low (A, C, E, and G) and high (B, D, F, and H) magnification. (Q) AGP protein expression in the liver was analyzed by Western blotting. (R–U) Expression of AGP protein in the liver was analyzed by immunohistochemistry. The nuclei were stained with hematoxylin (blue). SA-treated liver was analyzed at low (R) and high (S) magnification. RE-treated liver was analyzed at low (T) and high (U) magnification. Brown indicated AGP protein expression. (I–P) Expression of Hpx mRNA in liver analyzed by *in situ* hybridization. Sections of SA-, PV-, PT-, and RE-treated liver were hybridized with Hpx-specific probes and analyzed at low (I, K, M, and O) and high (J, L, N, and P) magnification. Brown signals represent Hpx expression.

detection and analysis of expression patterns of thousands of genes in a single experiment, and its sensitivity allows detection of subtle differences otherwise difficult to detect. In addition, DNA microarray-based approaches allow us to interrogate toxin-related genomes without bias as to which genes might be altered in expression.

Our histological study showed that RE-treatment severely decreased PAS-stained glycogen granules in hepatocytes.

Since hepatocytes are normally full of such granules, their loss suggests a severe load of toxic substances in liver cells [17]. As liver is a major detoxifying organ and analysis of pharmaceutical toxicity using the DNA array has been undertaken in liver [18], we considered liver an appropriate organ to analyze biological alterations with pertussis vaccine.

Based on analysis of 10,490 of rat genes, we identified 150 genes demonstrating significant changes either upward




Fig. 6. Quantitative PCR analysis of Agp and Hpx expression in RE-, PT-, PV-, and SA-treated liver. Gene expression of Agp (A) and Hpx (B) in liver treated with various concentrations of PT and RE were analyzed by Q-PCR. Agp and Hpx expression was assessed relative to rat β -actin. Duplicate data from each animal is shown as black and white bars. Three animals per group were analyzed. PT0.008, PT 0.008 μ g/ml; PT0.04, PT 0.04 μ g/ml; PT0.2, PT 0.2 μ g/ml; PT1, PT 1.0 μ g/ml; PT5, PT 5.0 μ g/ml. Asterisk denotes significant differences ($P < 0.05$) by the Student's *t*-test.

or downward in gene expression after RE-treatment. Among them, several metabolism-related genes, such as FABP (fatty acid-binding protein; U7558) and NaCT (Na⁺-coupled citrate transporter; NM_170668) showed the great increase in expression level. FABP participates in the uptake, intracellular metabolism and/or transport of long chain fatty acids. NaCT plays a role in cellular utilization of citrate in blood for the synthesis of fatty acids and cholesterol and for the generation of energy. The great increase of these genes may be correlated to the toxin-related state of starvation that requires urgent energy derived from fatty tissues.

Reduction in PAS-positive glycogen granules in the liver (Fig. 2) after RE-treatment is consistent with this finding. Gordon et al. have reported that toxic substrates induce abnormal PAS-staining in liver cells due to reduced glycogen granules [19]. Inflammation-related genes, such as MIF (U62326), AGP (J00695), and IL-1 β (NM_031512) are also up-regulated in RE-treated liver, suggesting that acute inflammation is induced by RE-treatment. In addition, many forms of P450 (NM_19303, M16654, NM_012730, X53477, J02868) are induced in the liver by RE treatment. Comparing gene expression among SA-, PT-, and RE-treated animals, we identified nine genes that were up-regulated in toxic conditions. As shown in Table 1, five genes participated in metabolism, and four genes participated in inflammation. Among them, Agp and Hpx showed unequivocal correlation with RE treatment both in the DNA microarray and histological analysis. AGP is a 41–43 kDa glycoprotein with several activities, such as immunomodulating effects and the ability to bind steroid hormones and other molecules [20,21]. Reportedly, AGP serum concentrations, which remain stable in physiological conditions (about 1 g/l in human and 0.2 g/l in rats), increase several-fold during acute-phase inflammatory reactions and AGP is considered as a major member of the positive acute phase protein family. HPX is a serum glycoprotein with a high affinity for heme, and it is produced by and secreted from the liver. It is also known as a scavenger/transporter of heme [22]. Previous studies indicate that purified HPX is an acute-phase reactant

with serum levels increasing several-fold following experimentally induced inflammation [23,24]. These two genes likely react to RE and PT through acute-phase inflammatory reactions. These findings suggest that these biomarkers may be useful to detect PT-induced toxicity in pertussis vaccines.

So far, conventional leukocytosis promoting tests can detect active PT contamination at concentrations greater than 5 μ g/ml. While PAS staining of glycogen granules in RE-treated hepatocytes was weak, hepatocytes treated with a high concentration of PT (5 μ g/ml) were normally stained with PAS. With our method, we detected Agp and Hpx at a 5 μ g/ml PT and the expression level of both genes was dose dependent on PT concentration (Fig. 6). These findings suggest that the gene expression analysis should be useful to detect the PT activity specifically as well as leukocyte-promoting tests. We could detect the different time course of the toxic effects observed as measured by gene expression analysis and leukocytosis. The specific gene expression of Agp and Hpx were observed at day 1 post-treatment, however the increase in WBC were only observed after 2 days. These findings suggest that new test takes the shorter testing period.

Many manufacturers are improving vaccine quality by new methods, such as by using cultured cell lines. However improvements in quality control are continuously required. Since microarray analysis can cover thousands of genes rapidly, it may revolutionize vaccine safety tests and in doing so increase our understanding of molecular mechanisms underlying vaccine toxicity. Given the small variability among test animals, such an approach could potentially reduce the number of animals assayed, alleviating in part ethical problems related to animal tests, which are important issues for regulators worldwide. This method can be used for safety evaluation of different vaccines, such as the emerging vaccine for high pathogenic influenza. So far, safety assessment of vaccines before licensing requires a long time period. Our present assay, with its high reproducibility and reliability, could considerably shorten that period.

Acknowledgments

The authors thank Dr. Hiroshi Yoshikura for helpful discussion and critical reading of the manuscript. The authors have no conflicting financial interests.

Note about research grants: This work was supported by Grants-in-Aid from the Ministry of Health, Labour and Welfare, Japan.

References

- [1] Bordet J, Gengou D. Le microbe de la coqueluche. *Ann Inst Pasteur* 1909;23:415–9.
- [2] Cone TJ. Whooping cough is first described as a disease sui generis by Baillou in 1640. *Pediatrics* 1970;46:522.
- [3] Sato H, Sato Y. *Bordetella pertussis* infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. *Infect Immun* 1984;46(2):415–21.
- [4] Pertussis. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editors. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. 9th ed. Washington DC: Centers for Disease Control and Prevention; 2006. p. 79–96.
- [5] Ministry of Health and Welfare, J.G. The minimum requirements of biological products of Japan 1986. Tokyo: Ministry of Health and Welfare; 1986.
- [6] Horiuchi Y, Takahashi M, Konda T, Ochiai M, Yamamoto A, Kataoka M, et al. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan. *Jpn J Infect Dis* 2001;54(5):167–80.
- [7] Iwasa S, Ishida S, Asakawa S, Kurokawa M. Lymphocytosis-promoting factor produced by *Bordetella pertussis*. *Jpn J Med Sci Biol* 1968; 21:363–8.
- [8] Morsel S. Studies on the lymphocytosis induced in mice by *Bordetella pertussis*. *J Exp Med* 1965;121:49–68.
- [9] Cyster JG, Goodnow CC. Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords. *J Exp Med* 1995;182(2): 581–6.
- [10] Ishida S, Kurokawa M, Asakawa S, Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. *J Biol Stand* 1979;7(1):21–9.
- [11] Sakamoto A, Imai J, Nishikawa A, Honma R, Ito E, Yanagisawa Y, et al. Influence of inhalation anesthesia assessed by comprehensive gene expression profiling. *Gene* 2005;356:39–48.
- [12] Ejiri N, Katayama K, Kiyosawa N, Baba Y, Doi K. Microarray analysis on Phase II drug metabolizing enzymes expression in pregnant rats after treatment with pregnenolone-16alpha-carbonitrile or phenobarbital. *Exp Mol Pathol* 2005;79(3):272–7.
- [13] Toyooka Y, Tsunekawa N, Takahashi Y, Matsui Y, Satoh M, Noce T. Expression and intracellular localization of mouse Vasa-homologue protein during germ cell development. *Mech Dev* 2000;93(1–2): 139–49.
- [14] Fujiwara Y, Komiya T, Kawabata H, Sato M, Fujimoto H, Furusawa M, et al. Isolation of a DEAD-family protein gene that encodes a murine homolog of *Drosophila vasa* and its specific expression in germ cell lineage. *Proc Natl Acad Sci USA* 1994;91(25):12258–62.
- [15] Kobayashi S, Ito E, Honma R, Nojima Y, Shibuya M, Watanabe S, et al. Dynamic regulation of gene expression by the Flt-1 kinase and Matrigel in endothelial tubulogenesis. *Genomics* 2004;84(1):185–92.
- [16] Ito E, Honma R, Imai J, Azuma S, Kanno T, Mori S, et al. A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumor 1 fusion protein of desmoplastic small round-cell tumor. *Am J Pathol* 2003;163(6): 2165–72.
- [17] Purushotham KR, Lockard VG, Mehendale HM. Amplification of chloroform hepatotoxicity and lethality by dietary chlordecone (kepone) in mice. *Toxicol Pathol* 1988;16(1):27–34.
- [18] Shipkova M, Spielbauer B, Voland A, Grone HJ, Armstrong VW, Oelrich M, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. *Transplantation* 2004;78(8):1145–52.
- [19] Gordon GJ, Coleman WB, Hixson DC, Grisham JW. Liver regeneration in rats with retrorsine-induced hepatocellular injury proceeds through a novel cellular response. *Am J Pathol* 2000;156(2):607–19.
- [20] Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. *Biochim Biophys Acta* 2000;1482(1–2):157–71.
- [21] Nishi K, Sakai N, Komine Y, Maruyama T, Halsall HB, Otagiri M. Structural and drug-binding properties of alpha(1)-acid glycoprotein in reverse micelles. *Biochim Biophys Acta* 2002;1601(2):185–91.
- [22] Tolosano E, Altruda F. Hemopexin: structure, function, and regulation. *DNA Cell Biol* 2002;21(4):297–306.
- [23] Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. *Clin Chim Acta* 2001;312(1–2): 13–23.
- [24] Muller-Eberhard U. Hemopexin. *Methods Enzymol* 1988;163:536–65.

IV. 資料

ワクチン等の国家検定に係わる国際動向と 我が国の現状と課題

日時：平成20年12月2日（火）14：00～17：30

場所：国立感染症研究所 村山庁舎 第一会議室（戸山庁舎共用第二会議室 二元放送）

ワクチン等の国家検定に係わる世界の現状を紹介し、日本における課題点の理解を目指します。

はじめに 宮村所長 14:00～14:10

座長 落合 雅樹（検定検査品質保証室）

(1) 欧米の検定制度の現状 14:10～14:40

布施 晃 感染症情報センター

(2) アジアの検定制度の現状 14:40～15:10

堀内 善信 医薬品医療機器総合機構

座長 加藤 篤（ウイルス第三部）

(3) WHO の関係専門委員会の最新動向 15:10～15:40

荒川 宜親 細菌第二部

(4) WHO の新しい検定指針 15:40～16:10

佐々木 次雄 医薬品医療機器総合機構

座長 高橋 元秀（細菌第二部）

(5) 日本の検定制度と品質保証 16:10～16:40

内藤 誠之郎 検定検査品質保証室

(6) 我が国の現状と今後の課題 16:40～17:10

渡邊 治雄 副所長



事務局
国立感染症研究所
国際協力室 中嶋・布施・松井・今井
検定検査品質保証室 山口
細菌第二部 高橋
電話：03-5285-1111（内線2911）

欧米の検定制度の現状

国立感染症研究所
感染症情報センター
布施 晃




本講演の内容は欧米の規制当局の公式見解を示すものではありません。

1. 欧州における生物製剤の 品質管理システム



2









欧州医薬品庁 EMEA
European Medicines Agency EMEA

- ・1995年1月設立
- ・欧州連合の外局
- ・欧州議会、欧州委員会規則に基づく
- ・ヒトおよび動物の医薬品評価と管理

10




中央審査 Centralised Procedure

1. 審査の特徴
- 承認されるとEU内で有効
 - 単一の商品名の使用の可能
 - 共通の添付文書の表示が可能 (20言語)
 - 審査期間(最長210日)

13

Committee for Medicinal Products for Human Use (CHMP)

専門委員会



ヨーロッパ医薬品評価報告

European public assessment reports (EPARs)
Committee for Medicinal Products for Human Use (CHMP)

医薬品の審査承認内容の要約
データも含まれる
リスク/ベネフィットの記載
ホームページ上で閲覧可能
各国語版

160 承認医薬品 (2006年)



欧州医薬品危機管理

European Risk-Management strategy (ERMS)

医薬品監視委員会
Pharmacovigilance Working Party

医薬品疫学と医薬品監視ネットワーク
European Network of Centers of
Pharmacoepidemiology and Pharmacovigilance

小児用医薬品監視ガイドライン

Guidance on paediatric pharmacovigilance

ワクチン監視ガイドライン

Guidance on pharmacovigilance on vaccines

16




欧州医薬品・健康管理局 EDQM
European Directorate of Quality of Medicines & Healthcare



17

EDQMの組織

• 所長: Susanne Keitel (October 2007~)
(経歴 Schering, BfArM, EMEA)



18

EDQMの役割

- 1 欧州薬局方
- 2 承認方法の適正化
- 3 製造と品質管理の標準化 (試験法、標準品)
- 4 欧州公認検定機関ネットワーク
European Net work of Official Medicines
Control Laboratories (OMCLs)



19

OMCLs

European network of Official Medicines Control Laboratories

- 設立: 1995年
- 構成: 欧州薬局方参加国 (EEA, EFTA)
オプサーバー国
- 役割
中央審査・承認
個別審査・相互承認
欧州検定 (OCABR)
Official Control Authority Batch Release

20



Official Control Authority Batch Release

欧州検定ガイドライン (OCABR)

CONTROL AUTHORITY BATCH RELEASE OF VACCINES

2008

(1) 1st Edition (2008) (2) 2nd Edition (2010) (3) 3rd Edition (2012)

1. サンプリング
2. 試験の方法
3. 自家試験記録 (SLP)

血液製剤: 8 (0)
ワクチン: 50 (3)
() は2008年改訂
細胞由来インフルエンザ
Viroosomalインフルエンザ
狂犬病ワクチン

Appearance
Haemagglutinin antigen concentration/density test
Bacterial endotoxin content
Purity (first 5 lots, each monovalent bulk)

**EC/EEA
検定合格証書**

↓

相互承認